Aeglea BioTherapeutics Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aeglea BioTherapeutics stock.
View analyst ratings for Aeglea BioTherapeutics or view top-rated stocks.

Wall Street analysts have given Aeglea BioTherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aeglea BioTherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Aeglea BioTherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Aeglea BioTherapeutics.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) announced its earnings results on Wednesday, August, 4th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.06. The biotechnology company had revenue of $13.70 million for the quarter, compared to the consensus estimate of $6.45 million.
View Aeglea BioTherapeutics' earnings history.

Aeglea BioTherapeutics' stock was trading at $5.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGLE shares have increased by 41.4% and is now trading at $7.61.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued 12 month target prices for Aeglea BioTherapeutics' stock. Their forecasts range from $12.00 to $20.00. On average, they anticipate Aeglea BioTherapeutics' share price to reach $15.67 in the next year. This suggests a possible upside of 105.9% from the stock's current price.
View analysts' price targets for Aeglea BioTherapeutics or view top-rated stocks among Wall Street analysts.

3 employees have rated Aeglea BioTherapeutics CEO Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among Aeglea BioTherapeutics' employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Aeglea BioTherapeutics include Amneal Pharmaceuticals (AMRX), Generation Bio (GBIO), CytoDyn (CYDY), Supernus Pharmaceuticals (SUPN), Nurix Therapeutics (NRIX), Zealand Pharma A/S (ZEAL), Aerpio Pharmaceuticals (ARPO), Vectura Group (VEGPF), Y-mAbs Therapeutics (YMAB), Travere Therapeutics (TVTX), Arcturus Therapeutics (ARCT), Kura Oncology (KURA), COMPASS Pathways (CMPS), Kronos Bio (KRON) and Madrigal Pharmaceuticals (MDGL).
View all of AGLE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea BioTherapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Kura Oncology (KURA), Aduro Biotech (ADRO), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX) and Dicerna Pharmaceuticals (DRNA).

(AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Aeglea BioTherapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.33%), Vanguard Group Inc. (4.27%), Nantahala Capital Management LLC (3.42%), Goldman Sachs Group Inc. (2.31%), Great Point Partners LLC (1.83%) and State Street Corp (1.54%). Company insiders that own Aeglea BioTherapeutics stock include Anthony G Quinn and Jonathan Alspaugh.
View institutional ownership trends for Aeglea BioTherapeutics.

AGLE stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Marshall Wace LLP, Marshall Wace LLP, BlackRock Inc., Northern Trust Corp, Vanguard Group Inc., California Public Employees Retirement System, and Russell Investments Group Ltd..
View insider buying and selling activity for Aeglea BioTherapeutics or view top insider-selling stocks.

AGLE stock was bought by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Altium Capital Management LP, Millennium Management LLC, Morgan Stanley, Morgan Stanley, JPMorgan Chase & Co., Renaissance Technologies LLC, and State Street Corp. Company insiders that have bought Aeglea BioTherapeutics stock in the last two years include Anthony G Quinn, and Jonathan Alspaugh.
View insider buying and selling activity for Aeglea BioTherapeutics or or view top insider-buying stocks.

Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AGLE stock can currently be purchased for approximately $7.61.

Aeglea BioTherapeutics has a market capitalization of $373.38 million and generates $3.89 million in revenue each year. The biotechnology company earns $-80,890,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

Aeglea BioTherapeutics employs 90 workers across the globe.

The official website for Aeglea BioTherapeutics is www.aegleabio.com.

Aeglea BioTherapeutics is headquartered at 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746.

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The biotechnology company can be reached via phone at (512) 942-2935 or via email at [email protected].